Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 2512345...1020...Last »

Biogen’s muscle drug Spinraza too costly for Britain

Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker.

Read More »

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics set an average price of $315,000 per year for the company’s newly approved Fabry disease treatment.

Read More »

India’s Hetero pulls heart drug from U.S.

A unit of India’s Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States amid a wider probe into cancer risks associated with the drug.

Read More »

GW Pharmaceuticals Slaps Price Tag on Cannabis-Based Epilepsy Drug

GW Pharmaceuticals revealed a $32,500 price for the company’s cannabis-based epilepsy drug Epidiolex.

Read More »

Trump says will make announcement on reducing drug prices

U.S. President Donald Trump said his administration would make an announcement on reducing drug prices, but he did not offer specifics.

Read More »

Bayer wins EU watchdog’s endorsement for wider Xarelto use

Bayer received the European Medicines Agency’s recommendation for widening the use of its blockbuster clot prevention drug Xarelto to include atherosclerosis patients, opening a potentially lucrative new market.

Read More »

Amgen’s new migraine drug hits insurance hurdles

Amgen Inc.’s push to get patients on its new $575 a month migraine drug before competition emerges in September 2018 is facing barriers from insurers.

Read More »

Bayer to phase out Essure birth control device in U.S.

Bayer will discontinue the sale of the healthcare company’s birth control product Essure in the United States.

Read More »

Swiss, German drugmakers join U.S. price freeze

European drugmakers Roche, Bayer and Merck KGaA became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine.

Read More »

Mylan signs U.S. license deal on Humira with AbbVie

AbbVie Inc. signed a U.S. licensing deal for Mylan NV’s proposed biosimilar to the mega-blockbuster drug Humira.

Read More »

U.S. court blocks sale of Indivior rival generic

Indivior Plc’s shares jumped more than 33 percent after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker’s bestselling opioid addiction treatment.

Read More »

Trump told Pfizer CEO price hikes hurt his drug plan: source

U.S. President Donald Trump called Pfizer Chief Executive Ian Read to say the company’s July 1 price hikes had complicated the administration’s drug pricing plans, prompting the company to defer its planned increases, according to a source familiar with the matter.

Read More »

Pfizer Raises Prices Of Forty-Plus Drugs Per Report

The Wall Street Journal reported that Pfizer increased the list prices for more than 40 of the pharma giant’s prescribed medications.

Read More »

U.S. District Court rules in favor of Lilly’s Alimta patent

A U.S. District Court ruled in favor of Eli Lilly’s patent on its Alimta vitamin regimen and prevented Hospira and Dr. Reddy’s Laboratories from launching generics until the patent expires.

Read More »

Consumer Group Pressures FDA to Pull Takeda’s Gout Drug from Market

Consumer advocacy group Public Citizen petitioned the FDA to pull Takeda’s gout treatment Uloric (febuxostat) off the market.

Read More »

More evidence of NSAID risk in early pregnancy

Using non-steroidal anti-inflammatory drugs (NSAIDs) around the time of conception significantly increases the risk of miscarriage in the first eight weeks of pregnancy, a study suggests.

Read More »

Soaring costs, loss of benefits top Americans’ healthcare worries: Reuters/Ipsos poll

Americans listed healthcare as the most important problem facing the country, according to Reuters/Ipsos polling.

Read More »

Payer Access Special Feature: Straining the system

Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.

Read More »

DTC Special Feature: Which color is it?

A recent study of DTC advertising appearing in the Journal of General Internal Medicine concluded that few broadcast ads are compliant with FDA’s guidelines. The reality, though, might not be so cut and dried.

Read More »

U.S. drug prices hit by insurer tactic against copay assistance: analysis

A recently adopted tactic by U.S. health plans to limit the financial assistance drugmakers provide directly to consumers for prescription medicines is taking a toll on drug prices, according to a new analysis.

Read More »

Page 1 of 2512345...1020...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2018 Focus: Biotech, Payer Access, DTC and more!

Subscribe

Ad Right Bottom

Main Navigation